Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) - Dent, R; Im, S A; Espie, M (J Clin Oncol, 2018)
(Suppl.)